FDA Delays Decision on Belite Bio’s Eye Disease Pill to May

By Dr. Zubair Khalid, DVM, MS, PhD ·

FDA Delays Decision on Belite Bio’s Eye Disease Pill to May

The U.S. Food and Drug Administration has pushed back its decision on Belite Bio’s experimental treatment for a rare genetic eye condition. The new action date is now set for May of next year, a three-month delay from the original timeline.

Belite Bio submitted an application for its oral therapy targeting a form of inherited retinal disease. The FDA requires additional time to review the data before making a final approval or rejection. The company did not specify the reason for the delay, but such extensions are common when regulators request more information or need to complete a thorough evaluation.

The treatment is designed for patients with a specific genetic mutation that causes progressive vision loss. If approved, it would be one of the few oral options available for this rare eye condition.

Why this matters in the life sciences: Regulatory delays are a routine but closely watched event in biotech. For rare disease therapies, each month of delay can affect patient access to potential treatments. The FDA’s extended review also signals that the agency is scrutinizing safety and efficacy data carefully, which is standard for novel drugs targeting small patient populations. This case highlights the ongoing challenge of bringing precision medicines for genetic disorders through the regulatory pipeline.

Source: original report

Related articles